



Alliance to leave no-one behind

14° CONGRESSO NAZIONALE Bergamo 14-16 Giugno 2022  
Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi



www.icar2022.it



## Elenco Oral Communications

Orario	ID	Title	Presenting Author
<b>15/06/2022 10.05 - 11.05 PrEP: new data and issues</b>			
10.05 - 10.15	<b>328</b>	<b>OC 1</b> Impact of SIMIT PrEP eligibility criteria on retention in care and new sexually transmitted infections acquisition	Roberto Rossotti, Milano
10.17 - 10.27	<b>327</b>	<b>OC 2</b> Sexually transmitted infection and adherence in an Italian access program of HIV pre-exposure prophylaxis (ItaPrEP)	Valentina Mazzotta, Roma
10.29 - 10.39	<b>158</b>	<b>OC 3</b> Prevalence of anal HPV infection among PrEP users screened through a self-administered Point-of-Care test: data from a community-based PrEP programme in Milan	Lorenzo Biasioli, Milano
10.41 - 10.51	<b>197</b>	<b>OC 4</b> PrEP use disclosure to sexual partners, friends and relatives: a psycho-social analysis	Alessandra Bianchi, Milano
<b>15/06/2022 11.10 - 12.10 Immunological efficacy of SARS-CoV-2 vaccine I</b>			
11.10 - 11.20	<b>286</b>	<b>OC 5</b> Poor humoral immunogenicity to SARS-CoV-2 vaccination in people living with HIV (PLWH) with low CD4 count	Alessandra Vergori, ROMA
11.22 - 11.32	<b>342</b>	<b>OC 6</b> Humoral immunogenicity to SARS-CoV-2 mRNA vaccine third additional/booster shot in people living with HIV (PLWH) by current CD4 count	Andrea Antinori, Roma
11.34 - 11.44	<b>239</b>	<b>OC 7</b> Longitudinal characterization of interferon and antibody response following vaccination against SARS-CoV-2 in patients with HIV-1 infection	Federica Frasca, Roma
11.46 - 11.56	<b>134</b>	<b>OC 8</b> T-cell and humoral responses to mRNA-1273 vaccine up to 6 months in late presenter people living with HIV (PLWH)	Matteo Augello, Milano
<b>15/06/2022 13.15 - 14.15 Metabolic issues in effective HAART</b>			
13.15 - 13.25	<b>238</b>	<b>OC 9</b> Role of Emtricitabine/Tenofovir Alafenamide/Bictegravir on metabolic and hepatic safety: data from Surveillance Cohort Long-term Toxicity Antiretrovirals/antivirals (SCOLTA) project	Nicola Squillace, Monza
13.27 - 13.37	<b>198</b>	<b>OC 10</b> Machine learning algorithm to predict weight change in ART experienced PWH	Federico Motta, Modena
13.39 - 13.49	<b>45</b>	<b>OC 11</b> In vitro model of adipocyte differentiation under TAF, TDF and INSTIs selective challenge	Maria Aurora Carleo, Napoli
13.51 - 14.01	<b>205</b>	<b>OC 12</b> Liver enzymes levels, metabolic and renal profile modifications after switching from TDF to TAF- based regimens among ART experienced PLWH in ICONA cohort	Mariacristina Polisenio, Foggia
<b>15/06/2022 14.30 - 15.30 COVID-19: clinical management</b>			
14.30 - 14.40	<b>248</b>	<b>OC 13</b> Home prescription treatment and mortality risk after hospitalization with symptomatic COVID-19 disease	Andrea Dessilani, Modena
14.42 - 14.52	<b>259</b>	<b>OC 14</b> In vivo efficacy of monoclonal antibodies and direct antiviral agents against the SARS-CoV-2 BA.1 and BA.2 Omicron sublineages	Valentina Mazzotta, Roma
14.54 - 15.04	<b>103</b>	<b>OC 15</b> Anemia is strongly associated with severity and mortality of COVID-19 in hospitalized patients	Nicolò De Gennaro, Bari
15.06 - 15.16	<b>305</b>	<b>OC 16</b> Clinical characteristics and outcomes of COVID-19 in vaccinated versus not-vaccinated hospitalized patients: data from an Italian reference hospital	Annalisa Mondì, Roma



Alliance to leave no-one behind

14° CONGRESSO NAZIONALE Bergamo 14-16 Giugno 2022  
Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi



www.icar2022.it



## Elenco Oral Communications

Orario	ID	Title	Presenting Author
<b>15/06/2022 15.35 - 16.35 Pathogenesis and Immunology</b>			
15.35 - 15.45	<b>88</b>	<b>OC 17</b> Impact of SARS-CoV-2 infection in a relevant three-dimensional human bronchial cell culture model of Cystic Fibrosis	Isabel Pagani, Milano
15.47 - 15.57	<b>177</b>	<b>OC 18</b> Oral immunity characterization in saliva from asymptomatic and severe COVID19 patients	Irma Saulle, Milano
15.59 - 16.09	<b>230</b>	<b>OC 19</b> Therapeutic monoclonal antibody treatment restores immune homeostasis and did not prevent the expansion of anti-SARS-CoV-2 adaptive immune response in mild/moderate COVID-19 patients	Rita Casetti, Roma
16.11 - 16.21	<b>224</b>	<b>OC 20</b> Evidence of extensive transcriptionally active HBV integrations involving genetic regions crucial for cell proliferation in the early phases of chronic infection even in the setting of limited liver damage	Stefano D'Anna, Roma
<b>15/06/2022 16.40 - 17.40 From HIV to SARS-CoV-2</b>			
16.40 - 16.50	<b>174</b>	<b>OC 21</b> Intact proviral DNA and chromosome integration sites in peripheral blood lympho-monocytes of early treated acute HIV infections	Isabella Abbate, Roma
16.52 - 17.02	<b>188</b>	<b>OC 22</b> Plasma, Intracellular and Lymph node Antiretroviral Concentrations and HIV DNA Change in Patients Treated During Primary HIV Infection: Results from the INACTION P25 Study	Amedeo De Nicolò, Torino
17.04 - 17.14	<b>231</b>	<b>OC 23</b> Efficacy, tolerability and pharmacokinetics of doravirine in the clinical setting	Silvia Fantino, Torino
17.16 - 17.26	<b>346</b>	<b>OC 24</b> Are Minions useful in the lab workflow? Comparison between long and short sequencing in COVID-19 surveillance	Bianca Bruzzone, Genova
17.28 - 17.38	<b>122</b>	<b>OC 25</b> In vitro activity of molnupiravir in combination with GC-376 or PF-07321332 against SARS-CoV-2	Anna Gidari, Perugia
<b>15/06/2022 17.45 - 18.45 Metabolic alterations: effect of drugs and diseases</b>			
17.45 - 17.55	<b>156</b>	<b>OC 26</b> From NAFLD to MAFLD: implications of change in terminology in PWH	Licia Gozzi, Modena
17.57 - 18.07	<b>161</b>	<b>OC 27</b> The pathway of NAFLD vs MAFLD toward significant fibrosis	Jovana Milic, Modena
18.09 - 18.19	<b>49</b>	<b>OC 28</b> With or Without TAF? What is the difference? Data from a real-life setting	Nicola Squillace, Monza
18.21 - 18.31	<b>257</b>	<b>OC 29</b> Impact of COVID-19 pandemic on incidence and prevalence of metabolic syndrome in PLWH	Rebecka Papaioannu Borjesson, Milano
<b>15/06/2022 17.45 - 18.45 Special issues in clinical HIV</b>			
17.45 - 17.55	<b>255</b>	<b>OC 30</b> Final immunovirological data from the p25- Italian Network of Acute HIV Infection (INACTION) cohort	Elena Bruzzesi, Milano
17.57 - 18.07	<b>186</b>	<b>OC 31</b> Effect of 12-week cART on gut mucosal immunity and microbiome in PHI	Mohamad Hadla, Milano
18.09 - 18.19	<b>273</b>	<b>OC 32</b> PLWH with advanced HIV disease are at higher risk for becoming difficult to treat: data from a large cohort of PLWH starting modern ART regimens	Roberta Gagliardini, Roma
18.21 - 18.31	<b>118</b>	<b>OC 33</b> Weight change in obese and overweight PWH: the impact of SARS-CoV-2 pandemic	Silvia Dettori, Genova



Alliance to leave no-one behind

14° CONGRESSO NAZIONALE Bergamo 14-16 Giugno 2022  
Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi



www.icar2022.it



## Elenco Oral Communications

Orario	ID	Title	Presenting Author
<b>16/06/2022 11.10 - 12.10 Resistance to antiretrovirals</b>			
11.10 - 11.20	24	<b>OC 34</b> Evaluation of integrase resistance and its predictors in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings	Maria Santoro, Roma
11.22 - 11.32	110	<b>OC 35</b> Efficacy of dolutegravir versus darunavir in first-line regimens according to resistance mutations and viral subtype	Pierluigi Francesco Salvo, Roma
11.34 - 11.44	79	<b>OC 36</b> Clinical and virological outcomes of difficult to treat patients in a large cohort of PLWH starting modern ART regimens	Roberta Gagliardini, Roma
11.46 - 11.56	114	<b>OC 37</b> Durability of Mega ART in a large cohort of treatment experienced people living with HIV: Data from ARCA database	Laura Labate, Genova
<b>16/06/2022 12.15 - 13.15 HIV and SARS-CoV-2 two intersecting epidemics</b>			
12.15 - 12.25	304	<b>OC 38</b> The Cascade of HIV Care (CoC) of Milan as compared to Italy: data derived from the COA Registry and the Icona cohort- Milan Fast Track City	Antonella d'Arminio Monforte, Milano
12.27 - 12.37	6	<b>OC 39</b> Effect of COVID-19 pandemic on the HIV cascade of care at a Provincial level	Franco Maggiolo, Bergamo
12.39 - 12.49	25	<b>OC 40</b> SARS-CoV-2 infection and vaccination coverage among fragile populations in a Local Health Area of Northern Italy	Samuele Storti, Brescia
12.51 - 13.01	57	<b>OC 41</b> New diagnosis of HIV among transgender women sex-workers across time: results from a multi-year street-based intervention (2017-2020)	Alice Ranzani, Monza
<b>16/06/2022 13.15 - 14.15 Diabetes, cardiovascular diseases and STIs. A wide range of comorbidities</b>			
13.15 - 13.25	71	<b>OC 42</b> Incident diabetes in course of antiretroviral therapy	Lucia Taramasso, Genova
13.27 - 13.37	279	<b>OC 43</b> Treatment with integrase inhibitors among antiretroviral naïve patients is not associated with increased risk of diabetes mellitus	Giuseppe Lapadula, Monza
13.39 - 13.49	277	<b>OC 44</b> Non-Alcoholic to Metabolic Associated Fatty Liver Disease: Cardiovascular Implications of a Change in Terminology in Patients Living With HIV	Jovana Milic, Modena
13.51 - 14.01	146	<b>OC 45</b> Syphilis infection and re-infection in PLWH and PrEP users: new insights into epidemic dynamics	Roberto Rossotti, Milano
<b>16/06/2022 13.15 - 14.15 Immunological efficacy of SARS-CoV-2 vaccine II</b>			
13.15 - 13.25	245	<b>OC 46</b> Monitoring saliva and plasma neutralizing activity induced by the administration of a third BNT162B2 vaccine dose	Micaela Garziano, Milano
13.27 - 13.37	282	<b>OC 47</b> Lower neutralization level against SARS-CoV-2 Omicron (BA.1) variant than against reference strain after a third dose of mRNA vaccine in PLWH	Alessandra Vergori, Roma
13.39 - 13.49	315	<b>OC 48</b> T-cell responses to SARS-CoV-2 Spike protein after 3 doses of BNT162b2 mRNA vaccination in healthy individuals, cross-recognize Alpha, Delta and Omicron variants of concern	Marco Iannetta, Roma
13.51 - 14.01	344	<b>OC 49</b> CD4 cell count is critical for specific T cell-mediated response in PLWH before and after third dose of COVID-19 vaccine	Eeva Tortellini, Roma



Alliance to leave no-one behind

14° CONGRESSO NAZIONALE Bergamo 14-16 Giugno 2022  
Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi



www.icar2022.it



## Elenco Oral Communications

Orario	ID	Title	Presenting Author
<b>16/06/2022 14.15 - 15.15 Dual therapy in naive and switched PLWH</b>			
14.15 - 14.25	5	<b>OC 50</b> Adherence rates and forgiveness to uncomplete adherence to 3TC/DTG	Franco Maggiolo, Bergamo
14.27 - 14.37	93	<b>OC 51</b> 12-Month immunological changes in patients randomized to switch either to BIC/TAF/FTC or DTG/3TC (DEBATE study)	Andrea Cossarizza, Modena
14.39 - 14.49	22	<b>OC 52</b> Switch to doravirine with dolutegravir dual regimen compared to other dual dolutegravir-based regimens in clinical practice: a 96-week analysis	Roberto Rossotti, Milano
14.51 - 15.01	149	<b>OC 53</b> Clinical and virological characteristics of people living with HIV who fail to maintain virological suppression after switching to dolutegravir-based two drug regimens. Results from the prospective observational ARCA cohort	Chiara Sepulcri, Genova
<b>16/06/2022 14.15 - 15.15 Mental health and predictors of AIDS and non-AIDS defining co-pathologies</b>			
14.15 - 14.25	14	<b>OC 54</b> Relation between genetic polymorphisms or variants and cognitive impairment in a group of HIV-infected people	Melania Degli Antoni, Brescia
14.27 - 14.37	153	<b>OC 55</b> A higher CPE score in PLWH with HAND switched to a less neurotoxic regimen is associated to improved memory test (MARAND-X study)	Alessandro Lazzaro, Roma
14.39 - 14.49	278	<b>OC 56</b> Pre-ART platelet-to-lymphocyte ratio and the risk of serious non-AIDS-events, AIDS-events and mortality in PLWH starting first-line ART	Paola Saltini, Milano
14.51 - 15.01	289	<b>OC 57</b> Association between HIV-1 DNA and clinical outcome in people living with HIV	Martina Bottanelli, Milano
<b>16/06/2022 15.20 - 16.20 Complexities of SARS-CoV-2 infection</b>			
15.20 - 15.30	242	<b>OC 58</b> Prevalence and epidemiological, clinical and microbiological characteristics of bacterial infections in a large cohort of patients admitted for COVID-19 in Campania: a multicentre cohort study	Lorenzo Onorato, Napoli
15.32 - 15.42	326	<b>OC 59</b> Evaluation of SARS-CoV-2 reinfection risk during the different COVID-19 variants' spread	Sara Leone, Roma
15.44 - 15.54	90	<b>OC 60</b> Pre-existent socio-economic status and its role in PASC syndrome: results from the VASCO study (VARIabili Socioeconomiche e COVID-19), on the "Surviving-COVID" Cohort, from Bergamo (Italy)	Simone Vasilij Benatti, Bergamo
15.56 - 16.06	162	<b>OC 61</b> Depressive Symptoms Among Covid-19 Survived Patients One Year After Hospital Discharge: Prevalence and Factors Associated	Paolo Vassalini, Roma
<b>16/06/2022 15.20 - 16.20 Insights on epidemiological and clinical management of hepatitis viruses</b>			
15.20 - 15.30	208	<b>OC 62</b> Serum HBsAg and highly-sensitive HBV-DNA quantification can predict HBsAg loss after nucleo(s)tide analogue systematic discontinuation in non-cirrhotic patients with chronic hepatitis B	Lorenzo Piermatteo, Roma
15.32 - 15.42	75	<b>OC 63</b> Hepatitis D virus infection in a large cohort of immigrants in Southern Italy a multicenter, prospective study	Emanuele Cordua, Napoli
15.44 - 15.54	192	<b>OC 64</b> Reactivation of hepatitis B virus is a frequent event in anti-HBc-positive/HBsAg-negative HIV-infected patients switching to Tenofovir sparing therapy as revealed by highly sensitive HBV assays	Romina Salpini, Roma
15.56 - 16.06	59	<b>OC 65</b> Hepatitis C testing, linkage to care and treatment during COVID-19 era in a north-east Italian hospital: what can we still need to do to improve elimination?	Elena Garlatti Costa, Pordenone